Busbee BG, Ho AC, Brown DM. et al. Twelve-month efficacy and safety of 0.5 mg or 2.0 mg ranibizumab in patients with subfoveal neovascular age-related macular degeneration. Ophthalmology 2013; 120: 1046-1056 doi:10.1016/j.ophtha.2012.10.014
Download Bibliographical Data
We do not assume any responsibility for the contents of the web pages of other providers.